The regulatory sciences for stem cell-based medicinal products

Abstract

Over the past few years, several new achievements have been made from stem cell studies, many of which have moved up from preclinical stages to early, or from early to middle or late, stages thanks to relatively safe profile and preliminary evidence of effectiveness. Moreover, some stem cell-based products have been approved for marketing by different national regulatory authorities. However, many critical issues associated mainly with incomplete understanding of stem cell biology and the relevant risk factors, and lack of effective regulations still exist and need to be urgently addressed, especially in countries where establishment of appropriate regulatory system just commenced. More relevantly, the stem cell regulatory sciences need to be established or improved to more effectively evaluate quality, safety and efficacy of stem cell products, and for building up the appropriate regulatory framework. In this review, we summarize some new achievements in stem cell studies, especially the preclinical and clinical studies, the existing regulations, and the associated challenges, and we then propose some considerations for improving stem cell regulatory sciences with a goal of promoting the steadfast growth of the well-regulated stem cell therapies abreast of evolvement of stem cell sciences and technologies.

Keywords

stem cell-based medicinal products (SCMPs) / stem cell therapy (SCT) / safety / effectiveness / standards / guidelines / regulatory science

References

[1] ISSCR Guidelines for Clinical Translation of Stem Cells. 2008

[2] De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12(5): 574−591

[3] FDA. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). 2008

[4] Chinese Ministry of Health and Family Planning & China Food and Drug Control Document. Interim Regulatory Guidance: guidelines for quality control and preclinical studies of the stem cell medicinal products. 2013

[5] Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D. A global regulatory science agenda for vaccines. Vaccine 2013; 31(Suppl 2): B163−B175

[6] clinicaltrials.gov website

[7] Olausson M. Bioengineered vascular graft with autologous stem cells: first use in the clinic. Regen Med 2012; 7(6 Suppl): 12−15

[8] Schulman IH, Hare JM. Key developments in stem cell therapy in cardiology. Regen Med 2012; 7(6 Suppl): 17−24

[9] Blenkinsop TA, Corneo B, Temple S, Stern JH. Ophthalmologic stem cell transplantation therapies. Regen Med 2012; 7(6 Suppl): 32−39

[10] Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17(4): 534−541

[11] Bersenev A. Regenerative Medicine and Cell Therapy Industry in 2012. RegenMed Digest. 2012.

[12] Barker RA. Stem cells and neurodegenerative diseases: where is it all going? Regen Med 2012; 7(6 Suppl): 26−31

[13] asianscientist.com website

[14] Annual Report ARM. Cellular Reprogramming and Disease Modeling. 2013. 24−26

[15] Bersenev A. Regenerative Medicine and Cell Therapy Industry in 2011. RegenMed Digest. 2011

[16] Bersenev A. Alliance for Regenerative Medicine’s 2012 Report. RegenMed Digest. 2012.

[17] McMahon DS, Thorsteinsdóttir H, Singer PA, Daar AS. Cultivating regenerative medicine innovation in China. Regen Med 2010; 5(1): 35−44

[18] Ministry of Heath Reports. Surveys of Stem Cell Clinical Studies and Uses in China. 2012

[19] Chinese Ministry of Health and Family Planning & China Food and Drug Control Document. Interim Regulatory Guidance: general requirements for conducting clinical studies of the stem cell-based medicinal products. 2013

[20] Chinese Ministry of Health and Family Planning & China Food and Drug Control Document. Interim Regulatory Guidance: qualification for institutions conducting studies of the stem cell-based medicinal products. 2013

[21] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315−317

[22] Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med 2011; 9(1): 29

[23] EMA. Guideline on Human Cell-Based Medicinal Products. 2007

[24] EMA. Reflection Paper on Stem Cell-Based Medicinal Pproducts. 2011

[25] FDA. Guidance for Human Somatic Cell Therapy and Gene Therapy. 1998

[26] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia. 2010 Version. Part III. Beijing: China Medical Science Press. 2010

[27] Guidelines for Clinical Studies and Quality Control of Human Somatic Cells (in Chinese). 2003

[28] WHO. Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks. 2010

[29] FDA. Guidance for Industry−Current Good Tissue Practice (CGTP) and Additional Requirements for Manufactures of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

[30] Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebé L; Société Française de Greffe de Moelle et Thérapie Cellulaire. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115(8): 1549−1553

[31] Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 2008; 43(11): 1018−1023

[32] Lazennec G, Jorgensen C. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26(6): 1387−1394

[33] Närvä E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P, Hovatta O, Otonkoski T, Tuuri T, Cui W, Brüstle O, Baker D, Maltby E, Moore HD, Benvenisty N, Andrews PW, Yli-Harja O, Lahesmaa R. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 2010; 28(4): 371−377

[34] Wong RS. Mesenchymal stem cells: angels or demons? J Biomed Biotechnol 2011; 2011: 459510

[35] Rayment EA, Williams DJ. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 2010; 28(5): 996−1004

[36] FDA. Guidance−Potency Tests for Cellular and Gene Therapy. 2011

[37] Werner M, Mayleben T, Van Bokkelen G. Autologous cell therapies: the importance of regulatory oversight. Regen Med 2012; 7(6 Suppl): 100−103

[38] Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen SE, Fleischmann BK. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110(4): 1362−1369

[39] Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, Hamad OA, Lönnies H, Magnusson PU, Sanchez J, Teramura Y, Nilsson-Ekdahl K, Ringdén O, Korsgren O, Nilsson B, Le Blanc K. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012; 30(7): 1565−1574

[40] US 21CFR211—Current Good Manufacturing Practice for Finished Pharmaceuticals

[41] US 21CFR312—Investigational New Drug Application

[42] US 21CFR610—General Biological Products Standards

[43] US 21CFR1271—Human Cells, Tissues, and Cellular and Tissue-Based Products

[44] US FDA. Draft Guidance—Preclinical Assessment of Investigational Cellular and Gene Therapy Products. 2012

[45] US FDA. Draft Guidance—Design of Early-Phase Clinical Trials. 2013

[46] George B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect Clin Res 2011; 2(3): 94−99

[47] US Pharmacopeia<1046>Cellular and Tissue-Based Products

[48] US Pharmacopeia<1043>Ancillary Materials for Cell, Gene and Tissue-engineered Products

[49] Hamburg MAIncreasing the Prestige of Regulatory Sciences. FDA Commissioner,s speech. 2011

[50] Wagner BJ. Cell standardization: purity and potency. Regen Med 2012; 7(6 Suppl): 89−92

[51] Buckler L. Why the stem cell sector must engage with social media. Regen Med 2012; 7(6 Suppl): 120−123

[52] Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013; 15(9): 1054−1061

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg